Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy

Acta Reumatologica Portuguesa

Volumn 37, Issue 3, 2012, Pages 253-259

  Duarte, R ^a,e,f,g   Campainha, S ^a,e,f   Cotter, J ^b,h   Rosa, B ^b,h   Varela, P ^c,f   Correia, A ^a,i   Canhao H ^d,j,k   Fonseca, J E ^d,j,k  

^a Portuguese Society of Pulmonology   (Portugal)

^b Portuguese Society of Gastroenterology   (Portugal)

^c Portuguese Society of Dermatology and Venereology   (Portugal)

^d Portuguese Society of Rheumatology   (Portugal)

^e Centro de Referência de Tuberculose Multi resistente da Região Norte   (Portugal)

^f Centro Hospitalar de Vila Nova de Gaia   (Spain)

^g University of Porto   (Portugal)

^h Centro Hospitalar do Alto Ave   (Portugal)

ⁱ Administração Regional de Saúde do Norte   (Portugal)

^j UNIVERSITY OF LISBON   (Portugal)

^k Hospital de Santa Maria (CHLN EPE)   (Portugal)

more..

Author keywords

Anti TNF drugs; Biological therapies; Immune mediated inflammatory diseases; Latent tuberculosis; Tuberculosis screening

Indexed keywords

ARTICLE; BIOLOGICAL THERAPY; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; MASS SCREENING; PRACTICE GUIDELINE; TUBERCULOSIS;

BIOLOGICAL THERAPY; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATION; MASS SCREENING; TUBERCULOSIS;

EID: 84868697226     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
2. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis and rheumatism 2005; 52: 1986-1992.
3. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of seriousinfection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-2376.
4. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alphatherapy. Arthritis Rheum 2003; 48: 3013-3022.
5. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significantincrease in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
6. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients withrheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-379.
7. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004; 39: 1254-1255.
8. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. The New England Journ Med 2001; 345: 1098-1104.
9. Vidal CG, Fernandez SR, Lacasa JM, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40: 756-759.
10. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001; 69: 1847-1855.
11. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761.
12. Fonseca JE, Lucas H, Canhão H, et al. Recomendações para diagnóstico e tratamento da tuberculose latente e activa nas doenças inflamatórias articulares candidatas a tratamento com fármacos inibidores do factor de necrose alfa. Rev Port Pneumol 2006;12:603-613.
13. Fonseca JE, Lucas H, Canhão H, et al. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update. Acta Reumatol Port 2008; 33:77-85
14. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-2293
15. De Keiser P. Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective. Current Rheumatology Reviews, 2011, 7, 77-87.
16. Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010;36:925-949.
17. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772.
18. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55: 19-26.
19. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-1206.
20. L P Ormerod, H J Milburn, S Gillespie, J Ledingham, D Rampton. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-a treatment. Thorax 2005; 60: 800-805.
21. Fonseca J et al. Recomendações para diagnóstico e tratamento da tuberculose latente e activa nas doenças inflamatórias articulares candidatas a tratamento com fármacos inibidores do factor de necrose tumoral alfa. Rev Port Pneumol 2006; XII: 603-613.
22. Lalvani A, Millington K. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmunity Reviews 2008; 8: 147-152.
23. Kezer I, Kocabas H, Melikoglu MA, Arman M. Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy. Clin Rheumatol 2009; 28: 53-57.
24. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59: 800-806.
25. Schatz M, Patterson R, Kloner R, Falk J. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population. Ann Intern Med 1976; 84: 261-265.
26. Ponce de Leon D, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1361.
27. Mori T. Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays. J Infect Chemoter 2009; 136: 198-204.
28. Pai M, Zwerling A, Menzies D. Systematic review: T-cell based assays for the diagnosis of latent tuberculous infection: an update. Ann Intern Med 2008; 149:177-184.
29. Vassilopoulos D, et al. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screeningin rheumatic patients scheduled for antitumor necrosis factor treatment. J Rheumatol 2008;35: 1464.
30. Sellam J, Hamdi H, Roy C, Baron G, Lehman M, Puechal X. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007;66:1610-1615.
31. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008;59:800-806.
32. Bartalesi F, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009;33:586-593.
33. Behar SM, Shin DS, Maier A et al. Use of T-SPOT. TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosupressive therapy. J Rheumatol 2009;36:546-551.
34. Keystone E, Papp L, Wobeser W. Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J Rheumatol 2011;38:1234-1243.
35. Pulimood AB, Peter S, Rook GW, et al. In situ PCR for Mycobacterium tuberculosis in endoscopic mucosal biopsy specimens of intestinal tuberculosis and Crohn's disease. Am J Clin Pathol 2008; 129: 846-851.
36. Kirsch R, Pentecost M, Hall P, DP Epstein, et al. Role of colonoscopic biopsy in distinguishing between Crohn's disease and intestinal tuberculosis. J Clin Pathol 2006;59:840-844.
37. Makharia G, Srivastava S, Das P, et al. Clinical, endoscopic, and histological differentiations between Crohn's disease and intestinal tuberculosis. Am J Gastroenterol 2010; 105: 642-651.
38. Park D, Kim J, Choi K, et al. Comparison of polymerase chain reaction with histopathologic features for diagnosis of tuberculosis in formalin-fixed, paraffin-embedded histologic specimens. Arch Pathol Lab Med 2003; 127: 326-330.
39. Amarapurkar D, Patel N, Amarapurkar A, et al. Tissue polymerase chain reaction in diagnosis of intestinal tuberculosis and Crohn's disease. J Assoc Physicians India 2004;52:863-867.
40. Kim K, Lee A, Choi K, et al. Intestinal tuberculosis: clinicopathologic analysis and diagnosis by endoscopic biopsy. Am J Gastroenterol 1998; 93: 606-609.
41. Gan H, Chen Y, Ouyang Q, et al. Differentiation between intestinal tuberculosis and Crohn's disease in endoscopic biopsy specimens by polymerase chain reaction. Am J Gastroenterol 2002; 97: 1446-1451.
42. Ramadass B, Chittaranjan S, Subramanian V, et al. Fecal polymerase chain reaction for Mycobacterium tuberculosis IS6110 to distinguish Crohn's disease from intestinal tuberculosis. Indian J Gastroenterol 2010;29:152-156.
43. Singh S, Verma R, Shah D. Molecular fingerprinting of clinical isolates of Mycobacterium bovis and Mycobacterium tuberculosis from India by restriction fragment length polymorphism (RFLP). J Vet Sci 2004;5:331-335.
44. Xian J, Joon K, Hyung K, et al. Histopathology and TB-PCR kit analysis in differentiating the diagnosis of intestinal tuberculosis and Crohn's disease. World J Gastroenterol 2010; 16: 2496-2503.
45. Amarapurkar D, Patel N, Rane P. Diagnosis of Crohn's disease in India where tuberculosis is widely prevalent. World J Gastroenterol 2008; 14: 741-746.
46. Almadi M, Ghosh S, Aljebreen AM. Differentiating intestinal tuberculosis from Crohn's disease: a diagnostic challenge. Am J Gastroenterol 2009; 104: 1003-1012.
47. Leung V, Law S, Lam C, et al. Intestinal tuberculosis in a regional hospital in Hong Kong: a 10-year experience. Hong Kong Med J 2006; 12: 264-271.
48. Balamurugan R, Venkataraman S, John KR, et al. PCR amplification of the IS6110 insertion element of Mycobacterium tuberculosis in fecal samples from patients with intestinal tuberculosis. J Clin Microbiol 2006; 44: 1884-1886.
49. Pulimood A, Amarapurkar D, Ghoshal U, et al. Differentiation of Crohn's disease from intestinal tuberculosis in India in 2010. World J Gastroenterol 2011 January 28;17:433-443.
50. Gan H, Ouyang Q, Bu H, et al. Value of polymerase chain reaction assay in diagnosis of intestinal tuberculosis and differentiation from Crohn's disease. Chin Med J (Engl) 1995;108:215-220.
51. Li J, Lo S, Ng C. Molecular detection of Mycobacterium tubercu losis in tissues showing granulomatous inflammation without demonstrable acid-fast bacilli. Diagn Mol Pathol 2000;9:67-74.
52. Preethi G, Venkatesh K, Navaneethan U. Mimickers of Intestinal Tuberculosis: Could this be Crohn's Disease? An Unsolved Enigma. Saudi J Gastroenterol 2011;17:95-96.
53. Soborg B, Ruhwald M, Hetland ML et al. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J. Rheumatol 2009; 36: 1876-1884.
54. Denkinger CM et al. Guidelines on interferon-gamma release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011; 17: 806-814.
55. Gomez-Reino JJ, Carmona L et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-761.
56. Brassard P, Kezouh A, Suissa A. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43:717-722.
57. Tubach F et al. Risk of tuberculosis is higher with anti-tumor necrosis factor receptor monoclonal antibody therapy than with solubletumor necrosis factor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894.
58. Wolfe F, Michard K, Anderson J et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2010; 50: 372-379.
59. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004; 1: CD000171.
60. Leung C, Rieder H, Lange C, Ywe W. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011; 37: 690-711.
61. Duarte R, Villa M, Carvalho A. Latent tuberculosis infection treatment. Current recommendations. Rev Port Pneumol 2010; XVI:809-814.
62. American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm. Rep. 2000; 49: 1-51
63. Public Health Agency of Canada and Canadian Lung Association. Canadian Tuberculosis Standards. Public Health Agency of Canada and Canadian Lung Association, Ottawa, 2007.
64. National Institute for Health and Clinical Excellence. Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. National Institute for Health and Clinical Excellence, London, 2006.
65. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: A meta-analysis. Clin Infect Dis 2005; 40: 670-676.
66. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: A randomized trial. Ann Intern Med 2008; 149: 689-697.
67. Page KR, Sifakis F, Montes OR, et al. Improved adherence and less toxicity with rifampin vs. isoniazid for treatment of latent tuberculosis: A retrospective study. Arch Intern Med 2006; 166:863-870.
68. Lardizabal A, Passannante M, Kojakali F, et al. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130: 1712-1717.
69. Aspler A, Long R, et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010; 65:582-587.
70. Kunst H, Khan K. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 2010; 14:1374-1381.
71. Kass J, Shandera W. Nervous System Effects of Antituberculosis Therapy 2010; 24: 655-667.
72. Snider DE Jr. Pyridoxina supplementation during Isoniazid therapy. Tubercul 1980; 61: 191-196.
73. Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008; 335: 126-136.